A5337: Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy

Study Location:

Washington

Topic:

HIV

Clinicaltrials.gov Link:

https://clinicaltrials.gov/ct2/show/NCT02440789?term=a5337&rank=1

IRB#:

Pro00013249

Coordinator:

Anna Wimpelberg

Enrollment:

Open

Trial Period:

Ongoing

When a person becomes infected with HIV the immune system (the system that helps fight infection) is weakened (partly because the number of CD4 cells goes down). Despite successful treatment with anti-HIV therapy, latent reservoirs (infected cells that are not actively producing HIV) remain in the blood and contribute to a process called immune system activation and inflammation in the body. This may contribute to HIV persisting in cells in the body even while taking medications to treat HIV.

  • HIV-infected men and woman, at least 18 years of age
  • Taking anti-HIV medications that have controlled the HIV viral load (“undetectable” levels) for 2 or more years.
    • Protease inhibitors and cobicistat are not allowed on this study.
  • CD4 cell count greater than or equal to 400 cells/mm3
  • No active hepatitis B or C infection, tuberculosis, or shingles
  • No vaccinations in the past 14 days.

Anna Wimpelberg 
202-797-3589
awimpelberg@whitman-walker.org

Categories

Location
Topic

Clinical Trials

A5322: Long-Term Follow-up of Older HIV-infected Adults in...

The A5322 protocol is a long-term observational study, with a planned series of analyses of data to be collected from an...

Read More

A5274: REMEMBER, Reducing Early Mortality and Early...

This study is being done in people who are starting HIV treatment and who live in areas where the TB infection rate is high. The...

Read More

A5314: Effect of LDMTX on Inflammation in HIV-infected...

A5314 is a phase II randomized, double-blind, placebo-controlled 36-week trial that will examine the safety and efficacy of...

Read More

A5225: Phase I/II Dose-Finding Study of High-Dose...

A5225/HiFLAC is a Phase I/II dose escalation and validation study of the safety, tolerability, and therapeutic effect of an...

Read More

A5354/EARLIER: Effect of Antiretroviral Treatment Initiated...

This study will include people who have very recently been infected with HIV and will start anti-HIV (antiretroviral) drugs...

Read More